Tuberculosis Program at NIAID

Slides:



Advertisements
Similar presentations
The Global Alliance for TB Drug Development
Advertisements

The TB Alliance-Bayer Moxifloxacin Deal
Gerald J. Siuta, Ph.D. Business Development May 3, 2007
Funding in Return for Rights Outside the Developed World: Public-Private Partnerships Gerald J. Siuta, Ph.D. Consultant, Business Development September.
Public/Private Partnerships in Global Health Initiatives
The Drug Discovery Process
Scaling up HIV services for women and children achievements and challenges e-lluminate session e-lluminate session Yves Souteyrand 2 March 2010.
Research: Critical for Global Health Insert Your Name & the Date of the Presentation Here.
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
TB and HIV Management Dr A.L. Pozniak Chelsea and Westminster Hospital London, UK.
1 TREATMENT AND PREVENTION SCALE-UP: THE SOUTH AFRICAN EXPERIENCE By Dr Moolman Team South Africa.
Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Moving Forward – Planning for Dr. Barbara Laughon Secretary, Working Group on New TB Drugs.
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.
June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.
Clinical Research at JHP LNM – 02 October OutlineJHU- Administration Building History Influential studies- ◦ PEPI ◦ 052 Future Prospects.
Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.
Role of the HIV/AIDS community in science & regulatory advocacy Nikos Dedes European AIDS Treatment Group 22 July 2014, Melbourne.
NIAID BioDefense Research: Challenges, Opportunities, & Sustainability
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
Funding of Cohort Studies Diana Finzi, Ph.D. Chief, Pathogenesis and Basic Research Branch Division of AIDS National Institutes of Health Bethesda, Maryland,
Rifapentine Development Progress – October 4, 2012 | 1 I. CIEREN-PUISEUX – ACCES TO MEDECINE Rifapentine Development Progress CPTR 2012 Workshop.
Working Group on TB Drugs
New York Product Development Partnerships for Global Health: The Global Alliance for TB Drug Development Gerald J. Siuta, Ph.D. Consultant, Business Development.
My Internship Experience with the National Institute of Health Summer 2014 Sidik Abdul-Mumuni USF-MPH Candidate.
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
Eight Week Randomized Trial of Treatment with Pa-824, Moxifloxacin, and Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Tuberculosis July 21, 2014.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
Community Representation Structure. Site Coordinating Centers (SCC) Community Advisory Boards (CABs) Leadership Level Cross-Network Level Network Level.
PDPs and Alternative IP Management/Tech Transfer Strategies for Improved Global Health Gerald J. Siuta, Ph.D. Consultant, Business Development Biotechnology.
The South African perspective
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
Colorado Department of Public Health and Environment Tuberculosis Prevention and Control Program.
Overview Pediatric HIV Program & IMPAACT/ PACTG Vaccine Research Children’s National Medical Center, Washington, DC Dr.Hans ML Spiegel Director Special.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.
HIV treatment for TB patients: priorities and ongoing research efforts Fabio Scano Stop TB, WHO TB/HIV meeting at 14 th conference on retroviruses and.
Tuberculosis Trials Consortium (TBTC) Overview Completed, Ongoing, and Moxifloxacin Clinical Trials Kenneth G. Castro, M.D. Assistant Surgeon General,
Human clinical trial of DNA-MVA HIV vaccine candidate begins A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector.
Issues in development for an MDR TB indication Leonard Sacks MD Division of special pathogens and transplant products FDA.
“28,424 cases of Ebola and still counting—what have we learned
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
HIV Testing for TB Patients in the Context of ART Scale-Up - Barriers to Implementation Kevin M. De Cock, MD CDC Kenya Geneva, February 14, 2005.
Update on the Development of a Group A Streptococcal Vaccine Fran A. Rubin, Ph.D. Program Officer for Group A Streptococci Respiratory Diseases Branch.
New Treatments to Reverse the Tide of TB Maria C. Freire, Ph.D. CEO & President.
A New Paradigm for TB Drug Development Mel Spigelman, M.D. Stakeholders’ Association Meeting October 17, 2005.
A model collaboration using the Pool Susanne Hollinger, Ph.D., J.D. Chief Intellectual Property Officer Emory University.
TB Alliance-Bayer Partnership Background Information.
NIAID Antimicrobial Resistance Research Efforts: Opportunities for the Global Community Dennis M. Dixon, PhD Chief, Bacteriology and Mycology Branch Division.
Moxifloxacin Development in TB Dr. Martin Springsklee VP, Therapeutic Area Head, Clinical Development Anti-Infectives Bayer HealthCare AG GATB Annual Stakeholder.
Key Tuberculosis Treatment and Prevention Issues
Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital
Community Advocacy & Education to End Stigmatizing HIV/TB Language
Community Advisory Boards on Repeat:
Private sector involvement IPM-Tibotec case study
Drug Development Coalition
African perspective on ethical guidelines Salim S Abdool Karim
Tuberculosis and the President’s Emergency Plan for AIDS Relief
C R E A E Consortium to Respond Effectively to the AIDS-TB Epidemic
Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson.
Division of AIDS Office of the Director Workforce Operations,
“State of the Alliance” The First 5 Years
Introduction to poster session and discussion
Every Mother, Every Child: Closing the Gaps in HIV Management
Testing Novel Combination Regimens
The IAS TB/HIV Research Prizes are awarded to:
Presentation transcript:

Tuberculosis Program at NIAID Christine Sizemore, PhD* & Barbara Laughon, PhD# *Program Officer for Tuberculosis, Leprosy and Other Mycobacterial Diseases #Chief, Complications and Co-Infections Research Branch, TRP Division of Microbiology and Infectious Diseases (DMID) Division of Acquired Immunodeficiency Syndrome (DAIDS) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) US Department of Health and Human Services (DHHS) NIAID – WHO TB/HIV February 14-15, 2005

New Therapeutics for Tuberculosis / HIV Co-infections Basic Research Preclinical Development Clinical Trials New Concepts for Therapeutics Growth Inhibition Screening Drug Libraries Mechanism-Based Screening In Vitro Spectrum In Vivo Efficacy Pharmacology Toxicology Multi-center Clinical Studies NIAID TBRU TB Alliance CDC TBTC ACTG International Sites IUATLD In Vivo Evaluation, Chemical Synthesis, Reagent Support, Data Bases NIH Roadmap Initiatives Direct Assistance and Interaction with the Scientific Community

NIAID Project Officer: Robert Goldman, www.taacf.org

Geographical Distribution of Compound Suppliers

Candidates Advancing >75,000 unique structures in database 7,157 active at < 6.25 ug/ml 2,000 MIC < 4 ug/ml 20 Actives in Gamma Knock Out Mouse 11 Actives in Standard Model 3 Actives in both GKO and Standard 182 Compounds in queue for in vivo testing Candidates = Compounds with SI >= 10, structural novelty, supportive assay results, meet drug-like criteria. NIAID Project Officer: Robert Goldman, www.taacf.org

Global Alliance for TB Drug Development (TB Alliance) TB Alliance founded in 2000 Global public private partnership NIAID - a founding stakeholder, in kind contributor NIAID staff – Board of Directors, Scientific Advisory Committee

Advanced Drug Development Moxifloxacin (Bayer) R207910 Diarylquinoline Johnson & Johnson PA-824 (TB Alliance) Oxazolidinone Ranbaxy Research Labs LL-3858 Lupin Pharmaceuticals SQ-109 Sequella, Inc KRQ-10018 KRICT/TB Alliance OSA FASgen, Inc PD Fluoroquinolone Thiolactomycin -GlaxoSmithKline/NIAID/St. Jude Children’s Hospital ActivBiotics

PA-824: Efficacy Review Bactericidal against replicating MTB New mechanism of action Active against MDR strains of MTB Potency similar to INH Other analogs show greater in vitro activity than PA-824, less in vivo Orally bioavailable with formulation

NIAID-supported TB HIV Co-infection Studies R Chaisson – “Novel TB Prevention Regimens for HIV-Infected Adults”, Hopkins, University of the Witwatersrand. R Oberhelman – “Practical Diagnostics for AIDS-Related Pediatric TB, Peru”, Tulane, Instituto de Salud del Nino, Lima. R Semba – “Adjunct Vitamin Therapy for TB and HIV/AIDS”, Hopkins, Zomba Central Hospital, Malawi C Whalen – “Punctuated ARV Therapy”, Case Western, Uganda JCRC, Kampala, Uganda A Salim Karim – “CIPRA:CAPRISA – Implementing ARV therapy in resource constrained settings”, Durban. D Havlir – AACTG 5221 "A Phase IV study of immediate versus delayed initiation of antiretroviral therapy for HIV-infected adults presenting with pulmonary tuberculosis.“ Sok Thim – “A Cambodian Clinical Research Network for HIV”, CAMELIA, Cambodian Health Committee (NGO), ANRS, Institute Pasteur Cambodia, Harvard. J Pape – “A randomized clinical trial to determine the efficacy of early versus delayed antiretroviral therapy in HIV-infected adults with CD4+ T cell counts between 200 and 350 cells/mm3”, GHESKIO, Haiti PACTG 1041 – “A Phase II/III Randomized DB Trial to Determine the Efficacy of INH in TB Disease in South African Infants Perinatally exposed to HIV”, University of the Witwatersrand, South Africa. J McIntyre – “CIPRA: The Effect of ART on Rates and Transmission of TB in a peri-urban community in South Africa”

TB HIV Co-Infection Treatment Issues Appropriate treatment of both infections When to Start ARVs in active TB What ARVs to Start – CYP interactions with PIs and with RIF How to effectively protect against infection (or re-infection) of HIV+ Extended INH over 6 months Lifetime INH Rifapentine Management and better understanding of the IRIS reaction in HIV/TB co-infections

Preclinical Efficacy Safety NIAID’s TB and other Mycobacterial Diseases Program Research Grants Fundamental and Clinical Science Vaccines Drugs Diagnostics Basic Research Target Identification Target Validation Candidate Identification Preclinical Efficacy Safety Optimization Scale-up GLP Pharm GLP Tox Formulation IND Studies Partners Clinical Trials Contracts